Search Results

San Diego, CA, April 30, 2026 (Globe Newswire) -- ResMed (NYSE: RMD) signed a definitive agreement to acquire Noctrix Health for $340 million, adding the company's FDA de novo-classified Nidra device to its sleep health portfolio. Nidra is a noninvasive nerve stimulation device for moderate-to-severe restless legs syndrome, the world's third most prevalent sleep disorder, affecting approximately 17 million people in the U.S. ResMed said Noctrix's revenue growth rate and gross margin both exceed its core business, and that Noctrix prescriptions flow through the same sleep physician and HME/DME channel where ResMed holds leading market share. The transaction is expected to close on or around June 1, 2026. Read full article here.

Wayne, PA, April 30,2026 (Business Wire) -- Teleflex has appointed Jason Weidman as its new president and chief executive officer. The leadership transition is intended to guide the company’s strategic priorities and operational execution. The move supports Teleflex’s focus on advancing its medical device portfolio and driving long-term growth. Read full article here.

Mumbai, India and Jersey City, NJ, April 26, 2026 (Business Wire) -- Sun Pharmaceutical Industries has signed a definitive agreement to acquire Organon in a transaction valued at approximately $3.1 billion. The acquisition is aimed at strengthening Sun Pharma’s presence in women’s health and established medicines across global markets. The deal is expected to expand its specialty portfolio and improve its international commercial footprint. Read full article here.

Stamford, CT and Boston, MA, April 15, 2026 (Globe Newswire) -- Beeline Medicines officially launched with $300 million in Series A financing led by Bain Capital, debuting with a portfolio of five clinical and preclinical programs in-licensed from Bristol Myers Squibb. The company's lead asset, afimetoran, is a once-daily oral TLR7/8 inhibitor for systemic lupus erythematosus currently in Phase 2, with data expected in the second half of 2026 ahead of a planned pivotal program. Read full article here.

Montreal and Highland Park, NJ, April 21, 2026 (Yahoo Finance) -- Modulari-T Biosciences has named Tanya E. Borsuk as its new chief executive officer. The leadership appointment is aimed at advancing the company’s strategic direction and accelerating development of its therapeutic platforms. The move positions the company to expand its pipeline and operational capabilities in the next stage of growth. Read full article here.

New York, NY, April 19, 2026 (PRNewswire) -- Pulnovo Medical closed an oversubscribed $100 million strategic financing round led by Medtronic, alongside existing investors EQT, Qiming Venture Partners, OrbiMed, Gaorong Ventures, and Lilly Asia Ventures, and new investor HSG (formerly Sequoia China). Separately, Medtronic and Pulnovo entered into a commercial agreement contemplating potential future commercialization opportunities. Read full article here.

Boston, MA, and Singapore, April 22, 2026 (Paratus) -- Paratus Sciences has appointed Alicia Secor as president and chief executive officer. The company also expanded its leadership team to strengthen operational and strategic capabilities. These changes are intended to support Paratus’ next phase of growth and advancement of its scientific programs. Read full article here.

San Diego, CA, April 19, 2026 (Reuters)  -- Eli Lilly has agreed to acquire Kelonia Therapeutics in a transaction valued at up to $7 billion. The deal includes an upfront payment along with additional milestone-based considerations tied to development progress. The acquisition is intended to strengthen Lilly’s oncology portfolio with next-generation cancer therapies. Read full article here.

Marlborough, MA and New York, NY, April 7, 2026 (Business Wire) -- Hologic announced the close of its go-private acquisition by Blackstone and TPG at up to $79/share and simultaneously named José (Joe) Almeida as CEO, effective immediately. Almeida was previously Chairman/President/CEO of Baxter International (2016–2025) and before that CEO of Covidien through its Medtronic acquisition. He succeeds Steve MacMillan, who retired after 12+ years. Read full article here .

Parsippany, NJ, March 24, 2026 (Yahoo Finance) -- Embecta has agreed to acquire Owen Mumford to strengthen its drug-delivery business. The transaction, valued at approximately $300 million, will add a range of injection and medical device products to Embecta’s portfolio. The deal is expected to enhance the company’s capabilities in supporting patients with chronic conditions. Read full article here .

Brisbane, CA, April 7, 2026 (ImpediMed) — ImpediMed has named Erik Anderson as its new chief executive officer. The leadership change is intended to guide the company’s strategic direction and support expansion of its medical technology portfolio. The appointment comes as ImpediMed focuses on advancing its commercial operations and growth initiatives. Read full article here .

San Diego, CA, April 7, 2026 (Yahoo Finance) -- Neurocrine Biosciences has outlined a transaction valued at approximately $2.9 billion aimed at expanding its therapeutic portfolio. The deal is designed to enhance the company’s pipeline with additional clinical-stage assets. The move supports Neurocrine’s strategy to drive long-term growth through targeted business development initiatives. Read full article here .